Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating Highlights
HOUSTON–(BUSINESS WIRE)–Kiromic Operating Highlights of 2Q-2021
Clinical Trials Updates | ||
IND Applications | Re-Submissions of two IND applications for ALEXIS product candidates: — ALEXIS-PRO-1: Off-the-Shelf, Allogenic CAR-T expressing chPD1 for Solid Tumors… |